AngioDynamics, Inc. reported a net loss of $8.1 million for the three months ended February 28, 2026, compared to a loss of $4.4 million in the same period last year. Revenue for the quarter increased by 8.9% to $78.4 million, driven by growth in both its Med Tech and Med Device segments, which saw increases of 19.0% and 1.2%, respectively. For the nine months ended February 28, 2026, the company recorded a net loss of $25.3 million, an improvement from a loss of $27.9 million in the prior year, with total revenue rising 10.0% to $233.6 million.

The company's gross margin for the quarter decreased to 52.9%, down from 54.0% a year earlier, while the nine-month gross margin increased to 54.9% from 54.4%. The Med Tech segment maintained a gross margin of 62.5%, while the Med Device segment's gross margin fell to 44.2%. The increase in revenue was attributed to strong sales of the Auryon thrombus management platform and NanoKnife, which contributed significantly to the Med Tech segment's growth.

Operationally, AngioDynamics has been focusing on restructuring its manufacturing footprint, which was announced in January 2024. This restructuring is expected to optimize efficiency and capabilities, with total restructuring charges recorded to date amounting to $33.2 million. The company also reported an increase in research and development expenses, which rose to $7.1 million for the quarter, reflecting ongoing investments in product development and clinical trials.

As of February 28, 2026, AngioDynamics had cash and cash equivalents totaling $37.8 million, down from $55.9 million at the end of the previous fiscal year. The company did not have any outstanding debt, and it continues to evaluate its liquidity position amid ongoing macroeconomic challenges, including inflation and supply chain issues. Looking ahead, AngioDynamics aims to expand its geographic reach and product offerings, with a focus on enhancing customer engagement and driving sales growth.

About ANGIODYNAMICS INC

AngioDynamics, Inc. is a diversified medical technology company focused on enhancing treatment options for cardiovascular diseases and cancer. Its key products include the Auryon Atherectomy System and various thrombus management devices. With a growing market opportunity, AngioDynamics targets interventional radiologists and oncologists. The company emphasizes innovation through R&D and strategic acquisitions, aiming to improve patient outcomes and expand its product offerings in the competitive medical device landscape.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.